An Israeli startup has partnered with China to improve existing drugs for eye diseases.
Everads Therapy uses a unique method to treat retinal diseases called “suprachoroidal delivery”.
It rapidly and safely delivers drugs to the back of the eye through the tissue that connects the middle (choroid) and outer coat (sclerotic) of the eyeball.
Everads will work together with VivaVision, a Shanghai-based pharmaceutical company, to develop potent molecules that will extend the durability of delivering drugs through the suprachoroidal space.
There were no available, reliable or efficient delivery technologies for suprachoroidal delivery until recently, when the FDA approved the first drug capable of doing so.
“We believe that VivaVision’s drug candidates and formulations offer significant potential for the treatment of retinal disease via suprachoroidal administration with our technology,” said Moshe Weinstein, CEO of Everads. “We look forward to working together to increase treatment safety, effectivity and durability.”
Wang Shen, CEO of VivaVision, said: “We are excited about the potential of delivering our treatments for posterior eye diseases through the suprachoroidal space using Everads’ technology, an approach that we believe will demonstrate strong efficacy and durability, potentially bringing life-changing improvements to populations throughout the world.”
Everads’s technology was licensed from the Sheba Tel HaShomer Medical Center in Ramat Gan, central Israel.
The company was founded in 2017, and is based in Tel Aviv.
Related posts

Israeli AI Safety Tool Among TIME’S Best Inventions For 2024

TAU Team Discovers Mechanism To Eliminate Cancerous Tumors

Ashdod Port Investing In Startups As Part Of Innovation Strategy

Facebook comments